Literature DB >> 7083220

Disposition and metabolic profile of a new antitumor agent: CL 216,942 (bisantrene) in laboratory animals.

W H Wu, G Nicolau.   

Abstract

A 14C-labeled antitumor drug, CL 216,942 (bisantrene), was administered iv at doses of 1-20 mg/kg to the monkey, dog, and rat. The serum concentration versus time profiles indicated at least a biphasic disappearance of the drug with long elimination half-lives of about 2-8 days in all three species. Total recoveries in the excreta collected through Day 7 were low (less than 50% of the administered dose), especially in the monkey and dog, with most of the drug found in the feces. Volumes of distribution in the central compartment as well as tissue distribution studies in all three species indicated a rapid uptake and significant concentration of the drug with long elimination half-lives in a deep compartment. The same organs and tissues (heart, liver, kidney, pancreas, spleen, lymph nodes, bone marrow, and most of the highly perfused glands) contained the highest drug concentrations in all three species. Metabolism studies indicated no evidence of significant biologic transformation of the drug in these species. In vitro studies by equilibrium dialysis indicated significant binding of the drug to DNA by intercalation.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7083220

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN: 0361-5960


  7 in total

1.  Blood and tissue concentrations of Bisantrene measured by a simple fluorometric assay.

Authors:  M Buck; J S Kovach
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

2.  Regional targeting of bisantrene by directed intravascular precipitation.

Authors:  J S Kovach; M Buck; T Tsukamoto; A Odegaard; M M Lieber
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

3.  A phase I and pharmacokinetic comparison of hepatic arterial and peripheral vein infusions of bisantrene for liver cancer.

Authors:  G R Weiss; M Hersh; J G Kuhn; T M Ludden; D D von Hoff; D L Kisner; T E Pirtle
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

4.  Characterization of the pharmacokinetics of bisantrene (NSC-337766).

Authors:  J G Kuhn; T M Ludden; J W Myers; D D Von Hoff
Journal:  Invest New Drugs       Date:  1983       Impact factor: 3.850

5.  Clinical pharmacokinetics of 9, 10-anthracenedicarboxaldehyde-bis [(4,5-dihydro-1 H-imidazol-2-yl)hydrazone]dihydrochloride.

Authors:  K Lu; N Savaraj; B S Yap; L G Feun; T Umsawasdi; T L Loo
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

6.  Sensitivity of human pancreatic carcinoma cell line (MIA PaCa-2) to Bisantrene and Theprubicin in vitro.

Authors:  G Fountzilas; L O Lim; A A Yunis
Journal:  In Vitro       Date:  1984-09

7.  In vivo and in vitro metabolism of the new anticancer drug bisantrene.

Authors:  Y M Peng; D S Alberts; T P Davis
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.